Biotech stocks slumped Wednesday, with Rapport Therapeutics (RAPP), Climb Bio (CLYM) and Cullinan Therapeutics (CGEM) among the hardest-hit names. All three come from the Medical-Development Biotech industry group. This includes more than 500 publicly traded biotech stocks whose companies who have yet to launch a commercial product.
The group fell a collective 4%. It ranks 30th out of 145 groups…
Extract — continue reading at the source.
Related stories
Record-breaking diesel prices are poised to hit grocery prices, with fruits, vegetables and meat first on the list
Rosneft billions fed Kremlin-backed money laundering network
Micron’s stock has become a ‘battleground’ as the AI narrative shifts
Bentley unveils its first fully electric car
The AI-scare trade is finally hitting banks. Bargain-hunters should take note.
Barrecore and Boom Cycle owner suddenly shuts studios